These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Hematological and iron parameters to predict mortality in ESRD]. Cantaro S, Piva E. G Ital Nefrol; 2005; 22 Suppl 31():S135-9. PubMed ID: 15786388 [Abstract] [Full Text] [Related]
23. [Amplitude of the distribution of erythrocyte size in the differential diagnosis of microcytic anemia]. Laso FJ, Mateos F, Ramos R, Herrero F, Pérez-Arellano JL, González-Buitrago JM. Med Clin (Barc); 1990 Jan 13; 94(1):1-4. PubMed ID: 2335971 [Abstract] [Full Text] [Related]
25. The interaction between heart failure and other heart diseases, renal failure, and anemia. Silverberg DS, Wexler D, Iaina A, Schwartz D. Semin Nephrol; 2006 Jul 13; 26(4):296-306. PubMed ID: 16949468 [Abstract] [Full Text] [Related]
30. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Belonje AM, Westenbrink BD, Voors AA, von Haehling S, Ponikowski P, Anker SD, van Veldhuisen DJ, Dickstein K. Am Heart J; 2009 Jan 13; 157(1):91-6. PubMed ID: 19081402 [Abstract] [Full Text] [Related]
31. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Am J Kidney Dis; 2006 Apr 13; 47(4):644-54. PubMed ID: 16564942 [Abstract] [Full Text] [Related]
37. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, Kohno S. Med Sci Monit; 2008 Sep 13; 14(9):CR431-7. PubMed ID: 18758412 [Abstract] [Full Text] [Related]